NCT01862315View on ClinicalTrials.gov

Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

March 18, 2025

Study Completion Date

March 18, 2025

Conditions

Intrahepatic CholangiocarcinomaPeripheral CholangiocarcinomaCholangiolar CarcinomaCholangiocellular Carcinoma

Interventions

DRUG

Floxuridine (FUDR)

DRUG

dexamethasone

DRUG

Gemcitabine

DRUG

Oxaliplatin

OTHER

MRI

OTHER

Research blood draws

These are optional

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

Unknown

Memorial Sloan Kettering Cancer Center, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

All Listed Sponsors

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01862315 - Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC) | Biotech Hunter | Biotech Hunter